28th May 2009
Insulin producer Bioton has officially informed the Labor Office of a plan to carry out mass lay offs from its current workforce of 635. The firm intends to reduce the number of staff by 170 employees with the first redundancies to begin in June.
"The reductions are the effect of the deteriorating economic situation and the necessity of limiting costs. The firm has to liquidate some jobs," reads Bioton's announcement to the Labor Office. The firm did not provide the anticipated savings it expects to make from the planned move, but analysts are surprised with the scale of redundancies nonetheless.
"I believe that the firm will incur costs of zł.25 million due to the restructuring of the Polish unit, including the costs of severance packages for employees," said Paweł Burzyński, an analyst with DM BZ WBK. However, according to his calculations the optimization of Bioton's employment level will enable the company to boost its operational result by some zł.11 million in 2010.
Source: Parkiet
From Warsaw Business Journal
Bioton-Sanofi deal
Bioton more than doubles net loss while restructuring
Bioton to sell Russian shares, focus on drug sales
Bayer to sell Bioton insulin in China
Bioton gets a shot in the arm











back
Download as PDF
Print this page
Go to top